Not to shabby!
$ImmunoPrecise Antibodies(IPA.US$ Financial Performance:
ImmunoPrecise reported a Q3 2024 revenue of $6.2 million, a 20.3% increase year-over-year.
Year-to-date revenue reached $18.1 million, showing a 20% rise from fiscal 2023.
The company reduced its net loss to $2.9 million or $0.11 per share from the previous year's loss of $4.7 million, or $0.19 per share.
Cash balance at the end of Q3 2024 was $6.2 million, compared to $8.3 million in the previous year.
R&D expenses were approximately $1 million for the quarter, significantly lower than the previous year.
Business Progress:
ImmunoPrecise made significant operational improvements by integrating BioStrand technology into their workflows, enhancing both scientific and commercialization initiatives.
The company expanded their facilities in Utrecht, Victoria, and Oss, and noted a significant performance in the B Cell program.
Their subsidiary BioStrand developed an AI model, LENSai, which improves precision in drug discovery and disease research, while reducing R&D costs.
The company has been expanding their VHH lead generation and gradually becoming more data-driven, underlining continual innovation.
ImmunoPrecise continues to integrate steady CRO revenue growth with in-silico technologies.
Strategic partnerships with pharmaceutical companies strengthen their tech validation, with plans for more collaborations.
ImmunoPrecise reported a Q3 2024 revenue of $6.2 million, a 20.3% increase year-over-year.
Year-to-date revenue reached $18.1 million, showing a 20% rise from fiscal 2023.
The company reduced its net loss to $2.9 million or $0.11 per share from the previous year's loss of $4.7 million, or $0.19 per share.
Cash balance at the end of Q3 2024 was $6.2 million, compared to $8.3 million in the previous year.
R&D expenses were approximately $1 million for the quarter, significantly lower than the previous year.
Business Progress:
ImmunoPrecise made significant operational improvements by integrating BioStrand technology into their workflows, enhancing both scientific and commercialization initiatives.
The company expanded their facilities in Utrecht, Victoria, and Oss, and noted a significant performance in the B Cell program.
Their subsidiary BioStrand developed an AI model, LENSai, which improves precision in drug discovery and disease research, while reducing R&D costs.
The company has been expanding their VHH lead generation and gradually becoming more data-driven, underlining continual innovation.
ImmunoPrecise continues to integrate steady CRO revenue growth with in-silico technologies.
Strategic partnerships with pharmaceutical companies strengthen their tech validation, with plans for more collaborations.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
